Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang"), stock code 301263. Taienkang was established in 1999. Its main business is agency operation and research and development, production, sales of pharmaceutical products, medical devices, sanitary materials, and providing medical technical services and technology transfer. The main products are Hewei Zhenchan Pills and "Wori" Ting" lecithin complex iodine tablets and "Aitingjiu" dapoxetine hydrochloride tablets.

Since its establishment, Taienkang has been agents and operated by Weizhen Chan Chan Wan and Wolitin. As the general agent of China, it is fully responsible for customs declaration, inspection, marketing promotion, distributor selection, sales pricing and other work in the Chinese market, and will promote its operations and promotion respectively. It has become a well-known product in the fields of gastrointestinal medicine and ophthalmic medicine in my country. After more than 20 years of marketing promotion, the company has formed a large-scale sales channel network and team. Through strong in-hospital channel control capabilities and innovative drug promotion models, products can quickly achieve sales revenue after they are launched.

In 2015, the company established a R&D subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. Based on the R&D strategy of "innovative drug research and development as the top, improved new drugs and biopharmaceuticals as the tower body, and generic drugs as the foundation", a functional auxiliary materials and nano-dose technology platform, a biomacromolecular drug technology platform and generic drugs have been built. Development and consistency evaluation technology platform. The company's independently developed "Aitingjiu" dapoxetine hydrochloride tablets is the "first imitation" in China. Tadalafil has obtained the drug registration approval document and obtained the first clinical trial of docetaxel polymer micelles for injection in China in 2018. Approval and signed a project transfer agreement with Fosun Pharma. In addition, the company also reserves a large number of independent drug research and development projects, among which Praxol Hydrochloride sustained release tablets, ornizolazone injection, and Agatroban injection have submitted drug registration approval applications, and ranibizumab injection is about to apply for clinical application. test. In the next three years, the company expects that the products under development will be approved for listing every year, which will continue to drive the company's product pipeline enrichment and rapid growth in profitability.